Efficacy and Safety of Adalimumab in Patients With Active Uveitis (VISUAL l)

• ClinicalTrials.gov Identifier: NCT01138657
• Recruitment Status: Completed
• First Posted: June 7, 2010
• Results First Posted: August 22, 2016
• Last Update Posted: July 7, 2021
• Sponsor: AbbVie (prior sponsor, Abbott)
• Information provided by (Responsible Party): AbbVie ( AbbVie (prior sponsor, Abbott) )

Tracking Information

• First Submitted Date: May 14, 2010
• First Posted Date: June 7, 2010
• Results First Submitted Date: July 11, 2016
• Results First Posted Date: August 22, 2016
• Last Update Posted Date: July 7, 2021
• Study Start Date: August 2010
• Actual Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: July 11, 2016)

Time to Treatment Failure on or After Week 6 [ Time Frame: From Baseline until end of study (up to 80 weeks) ]

Time to treatment failure was analyzed using Kaplan-Meier methods. Treatment failures on or after Week 6 were counted as events. Dropouts for reasons other than treatment failure at any time during the study were censored at the dropout date. To be considered a treatment failure, ≥ 1 of these criteria had to be present in at least 1 eye:

• New active, inflammatory chorioretinal or retinal vascular lesions relative to Baseline
• Inability to achieve ≤ 0.5+ at Week 6 or a 2-step increase relative to best state achieved at all visits after Week 6 in anterior chamber cell grade or vitreous haze grade
• Worsening of best corrected visual acuity by ≥ 15 letters relative to best state achieved.

Per protocol, the primary analysis was performed in the Main Study population which included all randomized participants recruited outside Japan; for completeness results are also reported below for the Integrated dataset which includes participants recruited in Japan.

Original Primary Outcome Measures (submitted: June 4, 2010)

Time to Treatment Failure [ Time Frame: As described above. ]

-Occurrence of one of following: New active, inflammatory chorioretinal and/or inflammatory retinal vascular lesions; Inability to achieve ≤ 0.5+ AC cell grade; Inability to achieve ≤ 0.5+ vitreous haze grade; Worsening of BCVA by ≥ 3 lines or 15 letters. Time Frame: Evaluated at the Week 6 visit -Occurrence of one of following: New active, inflammatory chorioretinal and/or inflammatory retinal vascular lesions; 2-step increase in AC cells; 2-step increase in vitreous haze; Worsening of BCVA by ≥ 3 lines or 15 letters. Time Frame: Evaluated at all visits after Week 6 (up to 80 weeks)

Current Secondary Outcome Measures (submitted: July 11, 2016)

• Change in Anterior Chamber (AC) Cell Grade in Each Eye From Best State Achieved Prior to Week 6 to the Final/Early Termination Visit [ Time Frame: From Baseline to Week 6 and at the Final/Early Termination Visit (up to 80 weeks) ]
  Slit lamp examinations were conducted at each visit to assess AC cell count. The number of AC cells observed within a 1 mm × 1 mm slit beam was used to determine the grade according to the Standardization of Uveitis Nomenclature (SUN) criteria: Grade 0 = < 1 cell; Grade 0.5+ = 1-5 cells; Grade 1+ = 6-15 cells; Grade 2+ = 16-25 cells; Grade 3+ = 26-50 cells; Grade 4+ = > 50 cells.
• Change in Vitreous Haze (VH) Grade in Each Eye From Best State Achieved Prior to Week 6 to the Final/Early Termination Visit [ Time Frame: From Baseline to Week 6 and Final/Early Termination Visit (up to 80 weeks) ]
  Vitreous haze was measured using dilated indirect ophthalmoscopy (DIO) and assessed by the Investigator according to National Eye Institute (NEI) and SUN criteria: Grade 0: No evident vitreous haze; Grade 0.5+: Slight blurring of the optic disc margin because of the haze; normal striations and reflex of the nerve fiber layer cannot be visualized; Grade 1+: Permits a better definition of both the optic nerve head and the retinal vessels (compared to higher grades); Grade 2+: Permits better visualization of the retinal vessels (compared to higher grades); Grade 3+: Permits the observer to see the optic nerve head, but the borders are quite blurry; Grade 4+: Optic nerve head is obscured.
• Change In Logarithm of the Minimum Angle of Resolution (LogMAR) Best Corrected Visual Acuity (BCVA) In Each Eye From Best State Achieved Prior to Week 6 to the Final/Early Termination Visit [ Time Frame: From Baseline to Week 6 and Final/Early Termination Visit (up to 80 weeks) ]
  Using corrective lenses based on that visit's refraction testing, participant's best corrected visual acuity was measured using an Early Treatment Diabetic Retinopathy Study (ETDRS) logMAR chart.
• Time to Optical Coherence Tomography (OCT) Evidence of Macular Edema in At Least 1 Eye On or After Week 6 [ Time Frame: From Baseline until the Final Visit (up to 80 weeks) ]
  Optical coherence tomography was performed at every visit using 1 of 3 approved machines. Images were evaluated by a central reader. Macular edema was defined as cystoid macular edema. OCT evidence of macular edema on or after Week 6 was to be counted as an event. Dropouts due to reasons other than OCT evidence of macular edema were to be considered as censored observations at the time of dropping out.
• Percent Change in Central Retinal Thickness in Each Eye From Best State Achieved Prior to Week 6 to the Final/Early Termination Visit [ Time Frame: Baseline to Week 6 and Final/Early Termination Visit (up to 80 weeks) ]
  Central retinal thickness was measured using optical coherence tomography and assessed by a central reader.
• Change in Visual Functioning Questionnaire 25 (VFQ-25) Composite Score From Best State Achieved Prior to Week 6 to the Final/Early Termination Visit [ Time Frame: Baseline to Week 6 and Final/Early Termination Visit (up 80 weeks) ]
  The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning. The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question. The overall composite score ranges from 0 to 100, where higher scores or increases in score indicate better vision-related functioning.
• Change in VFQ-25 Distance Vision Subscore From Best State Achieved Prior to Week 6 to the Final/Early Termination Visit [ Time Frame: Baseline to Week 6 and Final/Early Termination Visit (up 80 weeks) ]
  The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning. The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question. The distance vision subscore is calculated from the answers to 3 distance vision-related questions and ranges from 0 to 100, where higher scores or increases in score indicate better vision-related functioning.
• Change in VFQ-25 Near Vision Subscore From Best State Achieved Prior to Week 6 to the Final/Early Termination Visit [ Time Frame: Baseline to Week 6 and Final/Early Termination Visit (up 80 weeks) ]
  The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning. The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question. The distance vision subscore is calculated from the answers to 3 near vision-related questions and ranges from 0 to 100, where higher scores or increases in score indicate better vision-related functioning.
• Change in VFQ-25 Ocular Pain Subscore From Best State Achieved Prior to Week 6 to the Final/Early Termination Visit [ Time Frame: Baseline to Week 6 and Final/Early Termination Visit (up 80 weeks) ]
  The National Eye Institute VFQ-25 is an ocular disease-specific survey that measures the influence of visual disability and visual symptoms on generic health domains such as emotional well-being and social functioning, in addition to task-oriented domains related to daily visual functioning. The VFQ-25 consists of a base set of 25 vision-targeted questions plus an additional single-item general health rating question. The ocular pain subscore is calculated from the answers to 2 ocular pain-related questions and ranges from 0 to 100, where higher scores or increases in score indicate less pain.

Original Secondary Outcome Measures (submitted: June 4, 2010)

• Change in Vitreous Haze grade (NEI/SUN criteria) [ Time Frame: Baseline to final visit (Final Visit could occur at any point up to 80 weeks) ]
• Change in logMar BCVA [ Time Frame: Baseline to final visit (Final Visit could occur at any point up to 80 weeks) ]
• Time to OCT evidence of macular edema [ Time Frame: Evaluated at all visits after Week 6 (Final Visit could occur at any point up to 80 weeks) ]
• Change in central retinal thickness [ Time Frame: Baseline to final visit (Final Visit could occur at any point up to 80 weeks) ]
• Change in NEI Visual Functioning Questionnaire (VFQ-25) [ Time Frame: Baseline to final visit (Final Visit could occur at any point up to 80 weeks) ]

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Efficacy and Safety of Adalimumab in Patients With Active Uveitis
• Official Title: A Multicenter Study of the Efficacy and Safety of the Human Anti-TNF Monoclonal Antibody Adalimumab as Maintenance Therapy in Subjects Requiring High Dose Corticosteroids for Active Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis - Including a Sub-study in Japanese Patients
• Brief Summary: A study comparing the safety and efficacy of adalimumab compared with placebo in patients with active uveitis.
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment
• Condition: Uveitis

Intervention

• Biological: Adalimumab
  Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by a 40 mg dose eow starting at Week 1.
  Other Names:

  • ABT-D2E7
  • Humira
• Drug: Prednisone
  Administered orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all participants continuing in the study were to discontinue prednisone no later than Week 15.
• Drug: Placebo
  Administered by subcutaneous injection

Study Arms

• Experimental: Adalimumab
  Participants received adalimumab 80 mg subcutaneous loading dose at Baseline followed by 40 mg doses every other week (eow) starting at Week 1 for a maximum of 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper until Week 15.
  Interventions:

  • Biological: Adalimumab
  • Drug: Prednisone
• Placebo Comparator: Placebo
  Participants received placebo subcutaneous injection at Baseline followed by eow dosing starting at Week 1 for up to 80 weeks or until treatment failure. Participants continued to receive prednisone orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper until Week 15.
  Interventions:

  • Drug: Prednisone
  • Drug: Placebo

Publications *

• Jaffe GJ, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Kestelyn P, Barisani-Asenbauer T, Franco P, Heiligenhaus A, Scales D, Chu DS, Camez A, Kwatra NV, Song AP, Kron M, Tari S, Suhler EB. Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med. 2016 Sep 8;375(10):932-43. doi: 10.1056/NEJMoa1509852.
• Sheppard J, Joshi A, Betts KA, Hudgens S, Tari S, Chen N, Skup M, Dick AD. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials. JAMA Ophthalmol. 2017 Jun 1;135(6):511-518. doi: 10.1001/jamaophthalmol.2017.0603.
• Grewal DS, O'Sullivan ML, Kron M, Jaffe GJ. Association of Disorganization of Retinal Inner Layers With Visual Acuity In Eyes With Uveitic Cystoid Macular Edema. Am J Ophthalmol. 2017 May;177:116-125. doi: 10.1016/j.ajo.2017.02.017. Epub 2017 Feb 22.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: July 21, 2014): 239
• Original Estimated Enrollment (submitted: June 4, 2010): 250
• Actual Study Completion Date: August 2014
• Actual Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Subject is at least 18 years of age.
• Subject is diagnosed with non-infectious intermediate-, posterior-, or panuveitis.

• Subject must have active disease at the Baseline visit as defined by the presence of at least 1 of the following parameters in at least one eye despite at least 2 weeks of maintenance therapy with oral prednisone ≥ 10 mg/day to ≤ 60 mg/day (or oral corticosteroid equivalent):

  • Active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion
  • ≥ 2+ anterior chamber cells (Standardization of Uveitis Nomenclature [SUN] criteria)
  • ≥ 2+ vitreous haze (National Eye Institute [NEI]/SUN criteria)
• Subject is on oral prednisone ≥ 10 mg/day to ≤ 60 mg/day (or oral corticosteroid equivalent) for at least 2 weeks prior to Screening and remains on the same dose from Screening to Baseline visit.
• Subject with documented prior adequate response to oral corticosteroids (equivalent of oral prednisone up to 1 mg/kg/day).
• Subjects who do not have previous, active or latent tuberculosis (TB). Only one TB test is required to allow the subject in the study. Subjects with either negative purified protein derivative (PPD) (< 5 mm of induration) or negative QuantiFERON®-TB Gold test (or interferon-gamma release assay (IGRA) equivalent) are eligible. Subjects with a repeat indeterminate QuantiFERON®-TB Gold test (or IGRA equivalent) result are not eligible. Note, that only one TB screening test is allowed and required. A repeat QuantiFERON® TB Gold test (or IGRA equivalent) is not permitted if the PPD skin test is positive. The TB screening tests are diagnostic tests. In the event of a negative TB screening test, the results are to be interpreted in the context of the patient's epidemiology, history, exam findings, etc. and it is the responsibility of the investigator to determine if a patient has previous, active or latent tuberculosis or not. Under no circumstances can a patient with a positive PPD result or positive QuantiFERON®-TB Gold test (or IGRA equivalent) enter the study.

Exclusion Criteria:

• Subject with isolated anterior uveitis.
• Subject with prior inadequate response to high-dose oral corticosteroids
• Subject with confirmed or suspected infectious uveitis, including but not limited to infectious uveitis due to TB, cytomegalovirus (CMV), Human T-Lymphotropic Virus Type 1 (HTLV-1), Whipple's disease, Herpes Zoster virus (HZV), Lyme disease, toxoplasmosis and herpes simplex virus (HSV).
• Subject with serpiginous choroidopathy.
• Subject with corneal or lens opacity that precludes visualization of the fundus or that likely requires cataract surgery during the duration of the trial.
• Subject with intraocular pressure of ≥ 25 mmHg and on ≥ 2 glaucoma medications or evidence of glaucomatous optic nerve injury.
• Subject with Best Corrected Visual Acuity (BCVA) less than 20 letters (Early Treatment Diabetic Retinopathy Study) in at least one eye at the Baseline Visit.
• Subject with intermediate uveitis or panuveitis that has signs of intermediate uveitis (e.g.presence or history of snowbanking or snowballs) and symptoms and/or magnetic resonance imaging (MRI) findings suggestive of a demyelinating disease such as multiple sclerosis. All subjects with intermediate uveitis or panuveitis that have signs of intermediate uveitis (e.g., presence or history of snowbanking or snowballs) must have had a brain MRI within 90 days prior to the Baseline Visit.
• Subject has previous exposure to anti-tumor necrosis factor (TNF) therapy or any biologic therapy (except intravitreal anti-vascular endothelial growth factor [VEGF] therapy) with a potential therapeutic impact on non-infectious uveitis.

• If entering the study on 1 concomitant immunosuppressive therapy, dose has been increased within the last 28 days prior to Baseline visit or is not within the following allowable doses at the Baseline visit:

  • Methotrexate (MTX) ≤ 25 mg per week
  • Cyclosporine ≤ 4 mg/kg per day
  • Mycophenolate mofetil ≤ 2 grams per day or an equivalent drug to mycophenolate mofetil (e.g. mycophenolic acid) at an equivalent dose approved by the Medical Monitor.
  • Azathioprine ≤ 175 mg per day
  • Tacrolimus (oral formulation) ≤ 8 mg per day
• Subject has received Retisert® (glucocorticosteroids implant) within 3 years prior to the Baseline visit or that has had complications related to the device. Subject has had Retisert® (glucocorticosteroids implant) removed within 90 days prior to the Baseline visit or has had complications related to the removal of the device.
• Subject has received intraocular or periocular corticosteroids within 30 days prior to Baseline visit.
• Subject with proliferative or severe non-proliferative diabetic retinopathy or clinically significant macular edema due to diabetic retinopathy.
• Subject with neovascular/wet age-related macular degeneration
• Subject with abnormality of vitreo-retinal interface (i.e., vitreomacular traction, epiretinal membranes, etc.) with the potential for macular structural damage independent of the inflammatory process.
• Subject with severe vitreous haze that precludes visualization of the fundus at the Baseline visit.
• Subject has received Ozurdex® (dexamethasone implant) within 6 months prior to the Baseline visit.
• Subject has received intravitreal anti-VEGF therapy within 45 days of the Baseline visit for Lucentis® (ranibizumab) or Avastin® (bevacizumab) or within 60 days of the Baseline visit for anti-VEGF Trap (aflibercept).
• Subject has received intravitreal methotrexate within 90 days prior to the Baseline visit
• Subject on systemic carbonic anhydrase inhibitor within 1 week prior to Screening visit.
• Subject with macular edema as the only sign of uveitis.
• Subject with a history of scleritis.
• Subject with intolerance to high-dose oral corticosteroids (equivalent of oral prednisone 1 mg/kg/day or 60 to 80 mg/day).
• Subject on cyclophosphamide within 30 days prior to the Baseline visit.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Not Provided
• Removed Location Countries: Argentina, Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Denmark, France, Germany, Greece, Israel, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Spain, Switzerland, United Kingdom, United States

Administrative Information

• NCT Number: NCT01138657
• Other Study ID Numbers: M10-877; 2009-016095-68 ( EudraCT Number )
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: AbbVie ( AbbVie (prior sponsor, Abbott) )
• Original Responsible Party: Aileen Pangan, M.D./Medical Director, Abbott
• Current Study Sponsor: AbbVie (prior sponsor, Abbott)
• Original Study Sponsor: Abbott
• Collaborators: Not Provided

Investigators

• Study Director: Andy Payne, PhD; AbbVie

• PRS Account: AbbVie
• Verification Date: July 2021